Press Releases

    • December 21, 2018

    Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    December 19, 2018

    Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments

    LOUGHBOROUGH, England – Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    December 18, 2018

    Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    Read more
    December 18, 2018

    Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    December 17, 2018

    Nemaura Medical Announces Proposed Public Offering

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    December 12, 2018

    Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous...

    Read more
    December 4, 2018

    Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    Read more
    November 20, 2018

    Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous...

    Read more
    November 14, 2018

    Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    November 12, 2018

    Nemaura Medical to Present at the Stifel 2018 Healthcare Conference

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more